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The absence of a clear understanding of human chronic-
disease, especially the absence of a clear pathogenesis, has
hindered implementation of targeted predictive and preven-
tive medicine. But the emerging sciences of metagenomics
and proteomics have now clarified a mechanism whereby
not just one or two discrete pathogens can drive the disease
process, but where a very large number of viral, fungal and
bacterial species, accumulating in the human body over the
course of a lifetime, progressively weaken the human innate
immune system. Homo sapiens is not a sterile compart-
ment, but a super-organism harboring thousands of species
of microbes in its cells and tissues. Those microbes which
have evolved to persist inside nucleated and phagocytic
cells can engender both genomic and proteomic interfer-
ence within the host cell metabolism, precipitating the
disease processes. Key components of this microbiota
persist by reducing expression of, and by, the VDR Nuclear
Receptor, which is at the heart of the human innate immune
system. Only in Homo sapiens is the VDR responsible for
expression of Cathelicidin, TLR2, TACO and a number
of other endogenous anti-microbials. Animals have
different antimicrobial defenses, and thus cannot prop-
erly model human chronic disease. Pathogens already
known to persist by dysregulating the human VDR
include EBV, Mycobacteria, Borrelia, Aspergillus and
HIV. Antimicrobial therapy is difficult, as the diseased
VDR cannot be simply restored by endogenous metabolic
processes, as it can in healthy individuals. Nor can
antibiotics function in-vivo in the absence of a competent
innate immune system. We have shown that the drug
Olmesartan can be retargeted to function as a VDR
agonist, allowing innate immunity to recognize the
pathogens, and reverse the disease process. Recovery is
very slow, as care must be exercised to ensure the resulting
cytokine-storm does not become life-threatening. Over the
last decade, we have implemented a worldwide clinical
collaboration to demonstrate ‘proof of concept’ efficacy in
hundreds of subjects with serious chronic disorders,
ranging from schizophrenia and manic depression,
through ALS and MS, to sarcoidosis and arthritis. It
seems certain that the current epidemic of chronic disease
can not only be controlled, it can be reversed by
implementation of preventative measures aimed at mini-
mizing the accumulation of pathogenic organisms into the
human microbiome.
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Introduction: Diagnosis, treatment, prognosis of intracranial
suppurative complications after surgical interventions for
diseases and injuries of the nervous system and inflamma-
tory diseases of the upper respiratory tract is an important
problem of pediatric surgery. Of great and special impor-
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tance is a clinical and immune-mediated post-infectious
syndrome (CIPIS) to play a crucial role in the chronization
of the acute infections and to contribute to the development
of the disease-related complications.
Objectives: To study features of the immune responsive-
ness of patients with different clinical forms of intracra-
nial infectious and inflammatory processes (ICIIP), to
assess the clinical relevance of the data obtained and to
create a model of the ICIIP immunopathogenesis and
some of the typical forms of ICIIP associated with CIPIS
in the pathogenesis of ICIIP.
Materials and methods: 88 serum samples of patients with
ICIIP confirmed by imaging tests (CT, MRI) or during the
surgery (brain abscesses - 55; dural empyema - 25;
meningoencephalitis - 8) and 29 clinically healthy donors
have been studied. Cytometry was used for immunopheno-
typing of blood cell subsets; screening of cytokines, for
anti-tissue, anti-organ and antimicrobial antibodies (Abs) as
well as for B7-H1 biomarker by ELISA and cytometry;
identification of infectious pathogens was done by culture
and PCR.
Results: Two major forms of ICIIP-associated CIPIS have
been identified and confirmed, namely,
(1) postinfectious secondary immunodeficiency syndrome
(PISIS) - 92% of the total number of patients
(including aggressive subtypes: 38% and moderate
ones: 54%);
(2) PISIS associated with autoimmune syndrome (PISI-
DAS) – around 10% of patients.
ICIIP is characterized by the development of clinically
expressed subtypes of PISIS (38%), moderate types of
PISIS (54%), PISIDAS (10%). Specific features of
either of two syndromes have been established, namely,
for:(I) innate immunity and (II) effector link of adaptive
immunity and regulatory mechanisms of the immunity as
a whole.
Information obtained from the studies has given a way
to define two new classes of criteria to be implemented
into clinical and preclinical practice. The first class
would include microbiome-based criteria to monitor
spectrum and the localization of the microbial gene
pool and serologic profile anti-microbial Abs. The
second one would include immune-based criteria to
predict risks of transformation (predictive factor) of acute
forms of ICIIP into the chronic ones and development of
complications.
This study sets out the potential molecular and cellular
targets to be used for developing new drugs to treat CIPIS
and ICIIP and to predict the chronization as well as the
efficacy of therapeutic strategies in clinical and preclinical
stages of the disorder as the task of personalized medicine.
Further research is required to understand how CIPIS is
being developed in the preclinical stages and to develop
methods to perform clinically and pre-clinically (preven-
tive) applicable therapies for ICIIP.
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The Post-infectious clinical-immunological syndrome
(PICIS) variants include:
(1) Post-infectious secondary immunodeficiency syn-
drome (PIFSI);
(2) Post-infectious autoimmune syndrome (PIFA);
(3) PIFAS coupled with PIFA (PIFASID).
The incidence of the above listed syndromes in patients
with CID/CDIN differs statistically depending on the form
of the primary infectious pathology and the stage of the
destructive inflammatory process in target organs or tissues.
For example, the initial (including preclinical) stages are
usually concomitant with the predominant > 50%) forma-
tion of PIFSI, whereas the share of PIFA and PIFASID does
not exceed 20%.
This situation changes with further development and chron-
ization of the infectious process and its transformation into the
clinical phase, viz., and the share of autoimmune syndromes
increases substantially. In the intermediate stages of chroniza-
tion, the share of PIFA approximates 50%, while the share of
PIFASID in the final stages reaches 60%.
The frequency of PIFSI detection decreases appreciably
with the increase in the duration of the disease and
deterioration of cicatrical sclerotic lesions (to 25–40%);
that in the stage of pronounced substitution of the
parenchyma with connective tissue drops down to 10–15%.
The correlation between the stage of the disease and the
form of PICIS is characterized by the presence of an
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additional component, namely, the form and the clinical
course of the disease. There are some examples related to:
(1) Clinical form of the disease. In patients with primary
pyelonephritis (PPN) and infectious myocarditis (IM),
PIFSI occurs in 75% of cases, while in patients with
secondary pyeolnephritis (SPN) and autoimmune
myocarditis (AIM) the PIFSI ratio drops down to
25% giving way to autoaggressive symptomatology,
that is, the incidence of PIFA and PIFASID increases
(up to 60 and 85%, respectively).
(2) Period of disease: In early (less than 3 months for CPN
and less than a month for chronic myocarditis/CM)
stages of the disease, the incidence of PIFSI reaches
40%. However, its ratio diminishes with further prolon-
gation of the period of disease, while the contribution of
PIFA and PIFASID increases in contrast.
(3) Time scale of progression and chronization of
disease: In patients with a relapsing or rapidly
progressing course (e.g., ICIIP, AIM), the contribu-
tion of PIFSI does not exceed 32–36%, while that of
autoimmune syndromes amounts to 80–100%. It may
thus be concluded that PIFSI is not only an outcome
of the infectious disease, but, rather, is the major
factor responsible for its lingering and chronic
relapsing course. The role of progression and
chronization of the disease is defined, in a large
measure, by the form of PICIS or, rather, PIFA and
PIFASID, which reflect the picture of post-infectious
autoaggression.
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The association between microbial landscapes (microbiome)
and various immunopathological states with post-
infectious clinical-and-immunological syndrome (PICIS)
can be correlative or causal. In patients with chronically
relapsing infectious diseases (CRID), syndromal forms
of the immune-mediated disorders depend crucially on
the stage of the inflammatory process occurring in the
targeted organs or tissues and the overall chronization of
the disease.
For example, early stages of CRID are concomitant with
post-infectious secondary immunodeficiency syndrome
(PIFSI) (›50%), whereas the incidence and thus the
contribution of post-infectious autoimmune syndrome
(PIFA) and autoimmune syndrome associated with post-
infectious secondary immunodeficiency (PIFASID) do not
exceed 20%. At the subsequent stages, the clinical
manifestations are different, viz., the incidence and thus
the contribution of the autoimmunity rises dramatically: up
to 50% at the intermediate stages (PIFA) and up to 60% at
the final stage (PIFASID).
The correlation between the stage of CRID and the form of
PICIS is also characterized by the involvement of an
additional (the third) component, viz., a clinical form of
CRID. Here are several analytical examples related to:
(1) a clinical form of CRID: in patients with primary
pyelonephritis (PPNP) and infectious myocarditis
(IM), PIFSI is detected in 75% of clinical cases,
whereas in patients with secondary pyelonephrites
(SPNP) and autoimmune myocardites (AIM) the
contribution of PIFSI is notably reduced (to 25%)
giving way to the autoaggression (the incidence and
thus the contribution of PIFA and PIFASID increases
to 60% and 85%, respectively);
(2) a stage of CRID: at the early (including preclinical
ones) stages (<3 months for CPN and <1 month for
myocarditis (M)), PIFSI is detected in 40% of cases;
however, at the advanced stages of CRID its incidence
reduced appreciably, while that of autoimmune syn-
dromes increases in contrast;
(3) a rate of progression and chronization of CRID: in
patients with relapsing or rapidly progressing CRID
(e.g., ICIIP or AIM), the incidence and thus the
contribution of PIFSI do not exceed 32–36%, while
the share of autoimmune syndromes reaches 80–
100%. In such patients, persistent forms of chronic
meningoencephalitis (e.g., ICIIP) or AIM associated
with myocardial dystrophies are predominant.
These findings suggest that PIFSI is not only the outcome
of the infectious process, but also the predictive sign to
promote chronization of the disease and to represent a
factor responsible for getting the clinical course chronic.
Further progression and chronization of CRID are con-
trolled by post-infectious autoaggression factors, such as
PIFA and PIFASID which are thus also considered as
predictive factors to monitor transformation of subclinical
forms into the clinical ones.
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Introduction: The incidence and titers of serum autoanti-
bodies (autoAT) depend on the clinical manifestations of
autoimmune thyroid diseases and the expressiveness of the
autoaggression.Among anti-thyroid autoAbs the following
ones should be highlighted:
(1) canonical (anti-TG and anti-TPO) autoAbs and bispe-
cific (TG and TPO simultaneously) autoAbs (anti-
TGPO autoAbs);
(2) autoAbs with the functional properties: anti-TSH-R
autoAbs (TSH-R autoAbs), and autoAbs with proteo-
lytic activity (Ab-proteases).
Anti-thyroid autoAbs are occurring in patients with thyroid
dysfunction (hyper-or hypothyroidism: 55–90% of cases)
and in euthyroid individuals (3–8% of cases).
Canonical autoAT: Anti-thyroid autoAbs of different specific-
ities that dominat in Graves’ disease (70% and more), are
presented by canonical anti-TPO and anti-TG autoABs (60%)
and by anti-TGPO autoAbs (less 40%).Dynamics of anti-
thyroid autoAbs depends on the severity of the autoaggression
and would result in the decrease prior to the early stages of the
remission or to the burst at the exacerbation of the disease.
Therefore, preclinical diagnostic protocol could assess the
risks of Graves’ disease to progress, and to thus implement
the in-time therapeutic intervention to prevent the initiation
of the preclinical stages of the disease.
Anti-TG autoAbs:Anti-TG autoAbs in Graves’ patients
occur with a frequency of 50%.
Anti-TPO autoAbs:High-rate occurrence and serum titers of
anti-TPO autoAbs illustrate featured complications and
manifested forms of the disease (92–95% of cases), as well
as subclinical Graves’ disease (62–66%).
Anti-TGRO autoAbs:In Graves’ disease highly-enriched
populations of anti-TGPO autoAbs have been found.
Clustering thyroid autoAbs:The most common triplet found
in patients with manifested forms of Graves’ disease is a
serological panel of anti-TG-anti-TPO-anti-TGPO autoAbs
as well as duplexes of anti-TPO-anti-TGPO autoAbs. No
anti-TG-anti-TGPO duplexes have been identified in
Graves’ disease.
Functionally active autoAT: In patients with Graves’ disease
characterized by a high prevalence of functionally active
autoAbs, in particular, the TSH-R and Ab-proteases have
been dominated.
TSH-R autoAbs:TSH-R autoAbs classified as functionally
valuable Abs to mimic functions of the hormone and to
trigger the development of the Graves’ could be distin-
guished for two subtypes, i.e., TSH-stimulating (TCA) and
TSH-blocking (TBA) autoAbs.
AT-proteases:The prevalence of AT-proteases in patients
with Graves’ disease was reached to 77% to include
duplexes consisting of the TG-and TPO-Ab-specific
proteases simultaneously. In the early stages of Graves’
disease TPO-specific Ab-proteases are the only ones:
they are 50% of patients with subclinical Graves’
disease and 30% - with 0 goiter. The activity of Ab-
proteases increases during the destruction of the thyroid
(hypothyroidism): from stage to stage of the manifested
complicated course the activity increased in two or more
times.With a progression of the disease and the develop-
ment of hyperthyroidism is also identified a tendency for
the serological clustering.
Advanced serodiagnostic protocols: Currently there are no
defined serological criteria to allow for putting timely
diagnosis of Graves’ disease.Away of solving the problem
is the use of functionally active Abs (including Ab-
proteases).A role in solving the problems to verify
syndrome-like forms of the hyperthyroidism and/or to
identify the preclinical stages of the clinical illness and to
thus predict the latter would belong to Ab-proteases.
HUMAN CHITINASE-LIKE PROTEINS: NEW
BIOMARKER FAMILY
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Mammalian chitinase-like proteins (CLP) are induced at
sites of inflammation and in tumors. CLP are used as
investigative biomarkers for various human pathologies
including solid tumors (breast, colorectal, prostate cancers),
and cardiovascular disorders (atherosclerosis and its con-
sequences). The common structural feature of mammalian
chitinases and chitinase-like proteins is the presence of
conserved Glyco_18 domain. Function of chitinases in lower
life forms is a host defense against chitin-containing organ-
isms. There are 6 Glyco_18 domain containing proteins
identified in human up to date. Most recently, SI-CLP has
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been identified by us as a last chitinase-like protein which
secretion is regulated by receptor stabilin-1 in macrophages.
Human CLP comprise YKL-39, YKL-40, and SI-CLP. CLP
lack critical amino acids within the catalytic site and do not
exhibit enzymatic activity. Their biological activity is
defined by specific interactions mediated by enzymatically
silent Glyco_18 domain. Human CLP are secreted into the
extracellular space, and can be detected in tissues and in
blood circulation.
YKL-40 is the best investigated human CLP regarding its
association with various disorders. Circulating YKL-40 can
be detected in human serum or plasma using RIA or ELISA.
Increased concentrations of YKL-40 are associated with
disorders characterized by different types of inflammation
including asthma, arthritis, and atherosclerosis. Elevated
levels of YKL-40 were found in patients with various solid
tumors including breast cancer, colorectal cancer, ovarian
cancer, metastatic renal and prostate cancer and malignant
melanoma. High levels of YKL-40 are associated with poor
prognosis and rapid metastatic process. Levels of YKL-40
reflect difference in biology of cancer cells themselves as well
as activation tumor-associated macrophages.
YKL-39 was identified as an abundantly secreted protein in
primary culture of human articular chondrocytes. YKL-39
is currently recognized as a biomarker for the activation of
chondrocytes and osteoarthritis progression. For a long time
it was believed that macrophages do not secrete YKL-39.
However recently we demonstrated that key regulatory
factor of development, tumor progression and pathogenesis
of arthrosclerosis, TGFbeta, strongly stimulates YKL-39
expression in macrophages.
SI-CLP (stabilin-interacting chitinase-like protein) is the
most recently identified by us human CLP. Th2 cytokine IL-
4 and by dexamethasone induce expression of SI-CLP in
macrophages. We developed rat mAb 1 C11 that recognized
SI-CLP in the cellular fraction of bronchoalveolar lavage
obtained from patients with chronic inflammatory disorders of
the respiratory tract and in PBLs from these patients. SI-CLP
is the only CLP that is up-regulated by glucocorticoids. The
highest expression level of SI-CLP was found by us in a
patient with sarcoidosis undergoing glucocorticoid therapy.
We observed strong differences in effect of dexamethasone on
SI-CLP production in macrophages from different healthy
individuals. Thus, SI-CLP is a promising marker for the
individual response to glucocorticoids and prediction of side
effects of corticoid treatment. Our most recent data indicate
that SI-CLP is expressed in human colon carcinoma cells, but
not in breast or lung carcinoma cells indicating the perspective
for using SI-CLP as a cancer biomarker.
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Hidden immunopathologies play an important role in the
development of such life threatening diseases as athero-
sclerosis, including its potential consequences (heart attack
and stroke), cancer and dementia. Several cellular compo-
nents are responsible for the regulation of the activity of
immune system. The key regulatory role in this process is
played by monocytes and macrophages. Being distributed
in all tissues and organs of the human body macrophages
control its condition and guarantee timely and effective
reaction to damage, pathogen intrusion or transformed cell
appearance. After effective inflammatory reaction and
removal of the danger, macrophages initiate healing
processes and restore tissue homeostasis. Thus malfunction
of macrophages underlines most immune disorders.
We have reported that macrophages may adapt their
phenotype to changing microenvironment. According to
their pro- and anti-inflammatory activity macrophages can
be classified as type 1 (M1) and type 2 (M2) respectively.
Various pro- and anti-inflammatory stimuli are responsible
for high heterogeneity of macrophage phenotype in each
class. Type 1 macrophages produce pro-inflammatory
cytokines and express Fc-gamma receptors on the cell
surface. Type 2 macrophages produce anti-inflammatory
cytokines and chemokines and express various scavenger
receptors. The mechanism of macrophage activation is
highly complex and includes several signalling cascades,
vesicular trafficking and interaction of these two processes.
In case of immune system dysfunction blood monocytes
that have to be in inactive state gain properties of activated
macrophages and change their surface markers. The
analysis of a balance between pro- and anti-inflammatory
activities of primary human monocyte-derived macro-
phages is an attractive possibility for identification of
hidden immunopathologies. We have developed a test
system for the complex analysis of activation state of
primary human monocytes that provides highly valuable
information about the presence of immune system mal-
function before any clinical manifestation of a disease. This
system can be also used for the development of immuno-
correcting, anti-atherosclerotic and anti-cancer drugs.
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